Navigation Links
Targanta Submits Oritavancin New Drug Application
Date:2/11/2008

es in treating resistant bacterial infections, particularly those caused by MRSA. With Phase 3 trial results showing efficacy in only 3 to 7 days of treatment, we believe oritavancin may become part of a new treatment paradigm for infections caused by MRSA and other gram-positive bacteria, and could confer pharmacoeconomic benefits, if approved."

"Despite the introduction of several new antibiotics in the past decade, we continue to see an increase in the development of resistant gram-positive bacteria," said Peter Appelbaum, M.D., Ph.D., professor, division of clinical pathology and medical director, clinical microbiology at Penn State University. "There is an ongoing need for new bactericidal antibiotics that address the limitations of currently marketed therapies. Oritavancin has proven to be very potent in vitro against a broad spectrum of gram-positive organisms resistant to other agents. Also, due to its multiple mechanisms of action, oritavancin may hinder the rapid development of resistance; concordantly, contemporary surveillance studies have shown that oritavancin retains potency against all gram-positive organisms tested. The infectious disease community looks forward to adding a therapy with the characteristics of oritavancin."

More Background on the Market for Novel Antibiotics

There is a growing need for novel antibiotics since bacteria can mutate quickly and often develop resistance to existing antibiotics. Hospital-acquired infections are particularly likely to be resistant to existing antibiotics, but resistance is also growing rapidly in community- acquired infections. As bacteria become more resistant to currently marketed antibiotics, an increasing prevalence of drug-resistant bacterial pathogens can lead to increased mortality rates, prolonged hospitalizations, and increased healthcare costs.

About Targanta Therapeutics

Targanta Therapeutics Corporation is a biopharmaceutical company focused on developing and c
'/>"/>

SOURCE Targanta Therapeutics Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Targanta to Present at Lazard Capital Markets Fourth Annual Healthcare Conference
2. Targanta to Present at 9th Annual Mass Opportunities Investment Conference
3. Targanta Therapeutics Announces Pricing of its Initial Public Offering
4. Targanta Therapeutics to Have Significant Presence at 47th Annual ICAAC Meeting
5. MedImmune Submits Biologics License Application to FDA for Motavizumab
6. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
7. Exelixis Submits XL139 Diligence Report to Bristol-Myers Squibb
8. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
9. Cephalon Submits Supplemental New Drug Application for FENTORA
10. AMDL Submits Data to FDA for Clearance to Market Its DR-70(R) Diagnostic Test to Monitor Colorectal Cancer Patients
11. CV Therapeutics Submits Supplemental New Drug Application for Ranexa(R) (ranolazine extended-release tablets)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... , April 21, 2015  scPharmaceuticals, ... transformative pharmaceutical products for subcutaneous delivery, announced ... trial of its investigational proprietary drug product, ... edema associated with congestive heart failure. ... is developing a proprietary patch pump.  The ...
(Date:4/21/2015)... 2015 Progyny, Inc., the new combined ... that it has secured additional capital from investors including ... One and Merck Serono Ventures. The funding will enable ... best fertility outcomes by aligning science, technology, clinics and ... for families seeking fertility solutions and we are committed ...
(Date:4/21/2015)... (PRWEB) April 21, 2015 YourEncore, ... the life sciences, consumer products and food sciences ... and the Alliance for Clinical Research Excellence and ... system for conducting clinical research, have partnered to ... , YourEncore brings to ACRES experts ...
(Date:4/20/2015)... , April 20, 2015 Orthobiologics ... healing bone injuries. The orthobiologics market is a rewarding ... its stakeholders. The global orthobiologics market report defines and ... revenue. The global orthobiologics market was valued at $5,712.4 ... million by 2019, at a CAGR of 6.7% from ...
Breaking Biology Technology:scPharmaceuticals Announces Start of Pivotal Trial for Novel Furosemide Solution for Subcutaneous Delivery 2scPharmaceuticals Announces Start of Pivotal Trial for Novel Furosemide Solution for Subcutaneous Delivery 3Announcing Progyny: Combining Best-in-Class Clinical Solutions with Consumer Expertise 2YourEncore and ACRES Partner to Drive Innovation in Clinical Research 2YourEncore and ACRES Partner to Drive Innovation in Clinical Research 3Global Orthobiologics Market is Expected to Reach $7,900.2 Million by 2019, at a CAGR of 6.7% from 2014 to 2019 2Global Orthobiologics Market is Expected to Reach $7,900.2 Million by 2019, at a CAGR of 6.7% from 2014 to 2019 3
... technique long used by statisticians to analyze data is ... learning, Alzheimer,s and Parkinson,s diseases and stroke. Researchers ... Science Center at Houston (UTHealth) reported today in the ... fluorescence resonance energy transfer (FRET) techniques combined with wavelet ...
... / PRNewswire/ -- Sigma-Aldrich® Corporation (Nasdaq: ... intended to more closely align its corporate structure ... President Research, will assume responsibility for the entire ... Essentials, Research Specialties and Research Biotech.  This newly ...
... 2011 Chimerix, Inc., a pharmaceutical company developing orally ... awarded a contract by the Biomedical Advanced Research and ... broad spectrum antiviral drug candidate, CMX001, as a medical ... CMX001 is a potential dual-use therapeutic with ...
Cached Biology Technology:Researchers get a grip on nervous system's receptors 2Researchers get a grip on nervous system's receptors 3Sigma-Aldrich Announces Organizational Changes 2Sigma-Aldrich Announces Organizational Changes 3Chimerix Awarded BARDA Contract for Advanced Development of Broad Spectrum Antiviral CMX001 as Medical Countermeasure Against Smallpox 2Chimerix Awarded BARDA Contract for Advanced Development of Broad Spectrum Antiviral CMX001 as Medical Countermeasure Against Smallpox 3Chimerix Awarded BARDA Contract for Advanced Development of Broad Spectrum Antiviral CMX001 as Medical Countermeasure Against Smallpox 4
(Date:3/30/2015)... Mar. 26, 2015 Research and Markets ... "Global Gesture Recognition Market in Automotive Sector 2014-2018" ... forecast the Global Gesture Recognition market in Automotive Sector ... period 2013-2018. Gesture recognition is the ability ... gestures of an individual. Gesture recognition technology can be ...
(Date:3/24/2015)... 24, 2015   NexID Biometrics LLC, whose ... needs, today announced the beginning of shipments of version ... The company, based in Potsdam, N.Y. ... Connect:ID Expo, which began here today at the Walter ... 2.0 of its SDK boosts the accuracy rate range ...
(Date:3/23/2015)... 23, 2015  In the 2014 fiscal year, irs.gov ... losses. This figure accounts for a fraction of the ... Nilson Report, exceeds $11 billion globally. The polygraph has ... crime has occurred. Investor Mark Saint Juste ... Joe Paolella partnered to administer the test in ...
Breaking Biology News(10 mins):Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3
... FLA research team led by Cary Pirone from the ... identified bilirubin in the popular Bird of Paradise plant. ... of the American Society for Horticultural Science,s journal ... this iconic tropical plant. Previously thought to ...
... from door-to-door interviews, Stanford University geographer Eric Lambin and ... rise to a broad range of land-use challenges ... Lyme disease in Belgium. For decades, orbiting satellites ... of the Earth, giving scientists an unprecedented view of ...
... development and successful initial tests on a substance that ... a fungus, brightening prospects for wider use of the ... that attack food crops. "Our finding is especially important ... control treatments like this will help to reduce dependence ...
Cached Biology News:First discovery of bilirubin in a flower announced 2Stanford land-use expert brings satellite data down to Earth 2Stanford land-use expert brings satellite data down to Earth 3Stanford land-use expert brings satellite data down to Earth 4
Request Info...
Sterile glass 5 mm beads that make spreading bacterial and yeast cultures easy. Can be washed, autoclaved and reused....
... supplied as 10X concentrated solutions. REact Buffer SetConsists ... the REact buffers and one 250 microl vial ... 1 ml vials of REact 1 Buffer four ... 1 ml vials of REact 3 Buffer and ...
Request Info...
Biology Products: